FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

32963911000001104: Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 17-Aug 2016. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
1390181000001112 Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
1390191000001114 Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator EMA (European Medicines Agency) monitoring false Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Is a Selexipag 200microgram tablets 140 tablet true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has AMP Uptravi 200microgram tablets (Janssen-Cilag Ltd) true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has excipient Propylene glycol false Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has specific active ingredient Selexipag false Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Legal category Prescription only medicine - legal category (qualifier value) true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Discontinued indicator Never discontinued true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Is a Actual medicinal product pack true Inferred relationship Existential restriction modifier
Uptravi 200microgram tablets (Janssen-Cilag Ltd) 140 tablet Has specific active ingredient Selexipag true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group

This concept is not in any reference sets

Back to Start